Monte Rosa Therapeutics, Inc. Common Stock (GLUE)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Monte Rosa Therapeutics, Inc. Common Stock (GLUE) is listed on Nasdaq, where it has traded since June 24, 2021.
- Listed On
- Nasdaq
- Listed Since
- June 24, 2021
- Employees
- 173
- Market Cap
- $926M
About Monte Rosa Therapeutics, Inc. Common Stock
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 185 institutions reported holding GLUE, with 92.7 million shares worth $2.2 billion in aggregate. The largest reported holder was T. Rowe Price, with 8.9 million shares worth $214.4 million. Of the 5 largest holders listed below, 3 added shares and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| T. Rowe Price | 8,861,171 | $214M | Added 31.86% |
| Nea Management Company | 7,692,298 | $186M | Unchanged |
| BlackRock | 6,843,087 | $166M | Added 21.38% |
| Vanguard | 4,791,577 | $116M | Added 17.19% |
| Tcg Crossover Management | 4,622,151 | $112M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is GLUE?
Monte Rosa Therapeutics, Inc. Common Stock (GLUE) is listed on Nasdaq, where it has traded since June 24, 2021.
Who are the largest institutional holders of GLUE?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of GLUE were T. Rowe Price, Nea Management Company and BlackRock.
How many institutions own GLUE?
185 institutions reported a position in GLUE for the quarter ended June 30, 2026, worth $2.2 billion in total.
Did institutions buy or sell GLUE last quarter?
Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for GLUE.
Every reported institutional holder, plus insider and congressional trades in GLUE, on SentiSense.